title: Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
abstract: OBJECTIVE
  This study reports the results of proton beam radiotherapy based on a retrospective series of patients treated for uveal melanoma at the Orsay Center.
  
  
  METHODS
  Between September 1991 and September 2001, 1,406 patients with uveal melanoma were treated by proton beam radiotherapy. A total dose of 60 cobalt Gray equivalent (CGE) was delivered in 4 fractions on 4 days. Survival rates were determined using Kaplan-Meier estimates. Prognostic factors were determined by multivariate analysis using the Cox model.
  
  
  RESULTS
  The median follow-up was 73 months (range, 24-142 months). The 5-year overall survival and metastasis-free survival rates were 79% and 80.6%, respectively. The 5-year local control rate was 96%. The 5-year enucleation for complications rate was 7.7%. Independent prognostic factors for overall survival were age (p < 0.0001), gender (p < 0.0003), tumor site (p < 0.0001), tumor thickness (p = 0.02), tumor diameter (p < 0.0001), and retinal area receiving at least 30 CGE (p = 0.003). Independent prognostic factors for metastasis-free survival were age (p = 0.0042), retinal detachment (p = 0.01), tumor site (p < 0.0001), tumor volume (p < 0.0001), local recurrence (p < 0.0001), and retinal area receiving at least 30 CGE (p = 0.002). Independent prognostic factors for local control were tumor diameter (p = 0.003) and macular area receiving at least 30 CGE (p = 0.01). Independent prognostic factors for enucleation for complications were tumor thickness (p < 0.0001) and lens volume receiving at least 30 CGE (p = 0.0002).
  
  
  CONCLUSIONS
  This retrospective study confirms that proton beam radiotherapy ensures an excellent local control rate. Further clinical studies are required to decrease the incidence of postirradiation ocular complications.
authors.affiliation: Department of Radiation Oncology, Curie Institut, Paris, France. remi.dendale@curie.net
authors.forename: Rémi
authors.initials: R
authors.lastname: Dendale
authors.forename: Livia
authors.initials: L
authors.lastname: Lumbroso-Le Rouic
authors.forename: Georges
authors.initials: G
authors.lastname: Noel
authors.forename: Loïc
authors.initials: L
authors.lastname: Feuvret
authors.forename: Christine
authors.initials: C
authors.lastname: Levy
authors.forename: Sabine
authors.initials: S
authors.lastname: Delacroix
authors.forename: Anne
authors.initials: A
authors.lastname: Meyer
authors.forename: Catherine
authors.initials: C
authors.lastname: Nauraye
authors.forename: Alejandro
authors.initials: A
authors.lastname: Mazal
authors.forename: Hamid
authors.initials: H
authors.lastname: Mammar
authors.forename: Paul
authors.initials: P
authors.lastname: Garcia
authors.forename: François
authors.initials: F
authors.lastname: D'Hermies
authors.forename: Eric
authors.initials: E
authors.lastname: Frau
authors.forename: Corine
authors.initials: C
authors.lastname: Plancher
authors.forename: Bernard
authors.initials: B
authors.lastname: Asselain
authors.forename: Pierre
authors.initials: P
authors.lastname: Schlienger
authors.forename: Jean Jacques
authors.initials: JJ
authors.lastname: Mazeron
authors.forename: Laurence
authors.initials: L
authors.lastname: Desjardins
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D015353:Eye Enucleation / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008545:Melanoma / Q000401:mortality / Q000532:radiotherapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy / Q000601:surgery; D061766:Proton Therapy; D012189:Retrospective Studies; D015996:Survival Rate; D014604:Uveal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011522:Protons
chemical_list: D011522:Protons